Last reviewed: June 18, 2026
Last updated: June 18, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Recent preclinical and early clinical studies indicate that GLP-1 receptor agonists—medications traditionally prescribed for type 2 diabetes and weight management—may modulate reward-seeking behavior in the brain. A growing body of evidence suggests semaglutide and similar compounds could influence the neural circuits that drive addiction cravings, potentially opening a secondary therapeutic avenue for individuals struggling with substance use disorders or compulsive behaviors.
How GLP-1 Medications Target Addiction Pathways in the Brain
GLP-1 receptors are distributed throughout multiple brain regions, including areas associated with reward, motivation, and decision-making. When activated by semaglutide or other GLP-1 agonists, these receptors can dampen the dopamine response to addictive stimuli, potentially reducing the reinforcing 'high' that drives repeated use. This mechanism differs fundamentally from traditional addiction medications like naltrexone, which blocks opioid receptors, or methadone, which substitutes for heroin.
The ventral tegmental area and nucleus accumbens—core reward centers in the brain—show reduced activation in animal models exposed to GLP-1 agonists. This suggests the medications may quiet the motivational salience of addictive cues, making users less compelled to seek substances or engage in compulsive behaviors. The effect appears to extend beyond food-related reward, affecting broader hedonic pathways that underpin multiple forms of addiction.
Clinical Evidence: What Research Shows About GLP-1s and Cravings
A 2024 observational study of patients on semaglutide for weight loss reported significant reductions in alcohol cravings and reduced frequency of heavy drinking episodes, even in individuals not initially treated for alcohol use disorder. While not a randomized controlled trial, the findings prompted several research institutions to launch formal clinical trials investigating GLP-1 agonists as adjunctive therapy for addiction. Early-phase results have been encouraging but remain preliminary.
Research on tirzepatide, a dual GIP/GLP-1 receptor agonist, shows similarly promising signals for craving reduction across multiple substance classes, though human studies remain limited. Most evidence currently derives from rodent models and small observational cohorts, meaning larger randomized trials are essential before GLP-1 medications can be recommended as primary addiction treatments. The field is moving quickly, with major academic medical centers now enrolling patients in addiction-focused clinical trials.
Genetic Factors That May Influence GLP-1 Responsiveness to Addiction
Not all individuals respond equally to GLP-1 medications, and emerging research suggests genetic variation in GLP1R and other peptide-pathway genes may predict who experiences the strongest craving-reduction effects. Variants in the GLP1R gene (such as rs6923761) and the FTO gene (rs9939609) have been associated with differences in reward sensitivity and appetite control, traits that may also correlate with addiction vulnerability. PlexusDx's Precision Peptide Genetic Test maps 14 distinct pathways and 49 peptides, including markers relevant to dopamine signaling and reward regulation.
Understanding your genetic profile allows clinicians to tailor GLP-1 therapy more precisely—selecting compounds, doses, and adjunctive strategies based on your unique peptide-pathway biology. Individuals with specific GLP1R or MC4R variants may show faster craving reduction, while others may require longer titration periods or combination approaches. This personalized approach to addiction-adjacent GLP-1 use is still experimental but represents the direction precision medicine is moving.
PlexusDx Semaglutide and Personalized Addiction Support
PlexusDx offers compounded semaglutide injections from licensed 503A pharmacies, starting at $149 per month with no insurance required and HSA/FSA eligibility. For patients interested in exploring GLP-1 therapy for addiction-related cravings—whether alongside weight loss goals or as a standalone intervention under medical supervision—PlexusDx provides access to high-quality, affordable medication without membership fees or flat per-compound pricing increases. Your dose may need to go up; your price won't.
After your first month of treatment, you can add the Precision Peptide Genetic Test ($99) to identify genetic variants that predict your responsiveness to semaglutide across multiple pathways, including those involved in reward sensitivity and substance craving. This data empowers your PlexusDx provider to optimize your treatment plan, monitor efficacy for off-label addiction support, and adjust your regimen based on science rather than guesswork. PlexusDx serves all 50 states and works closely with prescribing clinicians to ensure safety and compliance.
Safety, Monitoring, and Next Steps for Addiction-Focused GLP-1 Therapy
While semaglutide is well-tolerated for weight loss and diabetes, using it specifically for addiction requires close clinical oversight, regular check-ins, and assessment of mental health status. Patients should not stop other evidence-based addiction treatments (like behavioral therapy or pharmacotherapy) in favor of GLP-1 monotherapy; rather, GLP-1 medications show promise as adjunctive agents. Common side effects include nausea, vomiting, and constipation, which typically diminish over time, but any worsening of mood or suicidal ideation should be reported immediately.
If you are considering semaglutide or another GLP-1 medication as part of comprehensive addiction care, discuss the latest research with your prescriber and explore whether PlexusDx's genetic testing could inform your treatment. The field is evolving rapidly, and new clinical trial data emerges regularly. PlexusDx clinicians stay current with emerging evidence and can guide you through the evidence base, the potential role of personalized peptide-pathway testing, and realistic expectations for craving reduction as part of a holistic recovery plan.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can semaglutide alone treat my addiction?
No. While emerging research suggests GLP-1 medications like semaglutide may reduce cravings, they should complement established treatments such as behavioral therapy, support groups, and medications like naltrexone or buprenorphine. Always consult your addiction medicine specialist before making changes to your treatment plan. PlexusDx semaglutide ($149/mo) can be used adjunctively under medical supervision, but is not a replacement for comprehensive care.
What is the scientific mechanism behind GLP-1s and addiction cravings?
GLP-1 receptors in the brain's reward centers (ventral tegmental area, nucleus accumbens) dampen dopamine responses to addictive stimuli when activated. This reduces the reinforcing effect of substances and compulsive cues, potentially lowering motivation to seek drugs or alcohol. Animal studies and early human observations support this model, but larger randomized trials are ongoing.
How much does PlexusDx semaglutide cost, and is it covered by insurance?
PlexusDx compounded semaglutide injections start at $149 per month and require no insurance. All plans are HSA/FSA eligible, and there are no membership fees or surprise your dose may need to go up - your price won't adjusts. PlexusDx serves all 50 states and makes medication affordable and accessible.
Are there side effects I should monitor if using semaglutide for addiction support?
Common side effects include nausea, vomiting, and constipation, typically diminishing over weeks. More serious concerns include pancreatitis symptoms, severe abdominal pain, or changes in mental health. If you experience worsening mood or suicidal thoughts, contact your provider immediately. Semaglutide requires regular clinical monitoring, especially in the context of addiction treatment.
How does the Precision Peptide Genetic Test help with addiction-focused GLP-1 therapy?
PlexusDx's Precision Peptide Genetic Test ($99 after first month) identifies variants in GLP1R, FTO, MC4R, and 46 other peptide-pathway markers that predict your likelihood of strong craving reduction and optimal dose responsiveness. This personalized insight allows your clinician to refine your semaglutide regimen and select adjunctive strategies tailored to your genetic biology, improving outcomes for addiction-related cravings.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Your Weight Loss Journey: Can You Take Ozempic with Mounjaro?
Navigating Your Path to Health: When Should I Take My Wegovy® Shot?